Molecular Partners (NASDAQ:MOLN) Issues Earnings Results, Misses Estimates By $0.03 EPS

Molecular Partners (NASDAQ:MOLN) released its quarterly earnings data on Tuesday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03), Zacks reports.

Molecular Partners Stock Down 5.1%

NASDAQ:MOLN traded down $0.21 during trading hours on Thursday, reaching $3.80. 611 shares of the stock were exchanged, compared to its average volume of 4,209. The business has a 50-day moving average of $4.36 and a two-hundred day moving average of $4.33. Molecular Partners has a twelve month low of $3.41 and a twelve month high of $5.36. The company has a market capitalization of $153.24 million, a price-to-earnings ratio of -1.96 and a beta of 1.08.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MOLN has been the topic of a number of recent analyst reports. TD Cowen reiterated a “buy” rating on shares of Molecular Partners in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a report on Friday, April 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Molecular Partners in a report on Wednesday, April 22nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.38.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.